Market capitalization | €827.58m |
Enterprise Value | €797.81m |
P/E (TTM) P/E ratio | 11.63 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 13.12 |
P/S ratio (TTM) P/S ratio | 13.61 |
P/B ratio (TTM) P/B ratio | 1.44 |
Revenue growth (TTM) Revenue growth | -11.42% |
Revenue (TTM) Revenue | €60.80m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
10 Analysts have issued a Formycon forecast:
10 Analysts have issued a Formycon forecast:
Jun '24 |
+/-
%
|
||
Revenue | 61 61 |
11%
11%
|
|
Gross Profit | 7.58 7.58 |
69%
69%
|
|
EBITDA | -23 -23 |
2,025%
2,025%
|
EBIT (Operating Income) EBIT | -25 -25 |
752%
752%
|
Net Profit | 64 64 |
251%
251%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205 which focusoin the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany.
Head office | Germany |
CEO | Stefan Glombitza |
Employees | 238 |
Founded | 2007 |
Website | formycon.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.